NextEra Falls, Seagate Slips, Regeneron Tumbles | Stock Movers

May 18, 2026Channel
AI Analysis
Data from YouTube Data API v3Updated Just now

Video Overview

Video Details

Published3 weeks ago
Duration3:44
Video IDlw3aink8VSA
Languageen
CategoryNews & Politics
PrivacyPublic
Made for KidsNo
Video TypeRegular Video

Performance Metrics

Views50
Likes0
Comments31
Engagement Rate62.00%
Likes per 100 views0.00
Comments per 1K views620.00

Description

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that’s struggling to meet the surge in electricity consumption. Dominion shares rose 9.4% to $67.56 as trading closed in New York on Monday, while NextEra fell 4.6% to $89.04. -Seagate (STX) shares fell 6.9% Monday in its worst one-day drop in nearly two months after management comments at a JPMorgan conference sparked investor fears that the company won’t be able to keep up with soaring demand for memory chips. The declines come after a blistering rally in the sector that’s spanned roughly eight weeks, boosted by solid earnings from megacap technology hyperscalers, a slew of deals for the cohort and investor enthusiasm in the risk-on trade as high demand for artificial intelligence infrastructure persists. The SOX gained nearly 60% from the start of April through a May 11 record high. - Regeneron Pharmaceuticals (REGN) said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron’s experimental drug fianlimab couldn’t beat Merck & Co.’s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.’s Opdualag continues. The shares plunged in trading on Monday. See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information. Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street. Check out more episodes of Stock Movers: https://www.youtube.com/playlist?list=PLe4PRejZgr0NxhJreY_kjMBdW8cvmNauU Visit us: https://www.bloomberg.com/podcasts Follow Bloomberg Podcasts on Twitter: https://twitter.com/podcasts Visit our other YouTube channels: Bloomberg Television: https://www.youtube.com/@markets Bloomberg Originals: https://www.youtube.com/bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake For coverage on news, markets and more: http://www.bloomberg.com/video #Stocks #Markets #Finance #Investing #Podcast #Bloomberg NextEra Falls, Seagate Slips, Regeneron Tumbles

Related Videos

More videos from Bloomberg Podcasts